Deep search
All
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Search
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo Nordisk to cap insulin prices in Minnesota settlement
Novo Nordisk to cap insulin prices in Minnesota settlement; joins Lilly, Sanofi
Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of charging astronomically high prices for the diabetes drug.
Minnesota AG announces Novo Nordisk settlement capping monthly insulin payments at $35
Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers following its 2018 lawsuit over unaffordable prices that led several diabetics to ration their medications with fatal consequences.
Novo Nordisk insulin now $35 per month for Minnesotans thanks to Attorney General Keith Ellison
Attorney General Keith Ellison announced a settlement with Novo Nordisk that let's Minnesotans buy its insulin products for $35 per month.
AG Ellison settles with Novo Nordisk to cap out-of-pocket payments for insulin at $35 a month
Minnesota A.G. Keith Ellison says his office settled with Novo Nordisk to cap monthly out-of-pocket payments for insulin at $35 a month.
MN Novo Nordisk settlement over insulin pricing [RAW]
Minnesota Attorney General Keith Ellison announced a settlement with Novo Nordisk regarding the high price of insulin. The settlement requires Novo Nordisk to offer its insulin products to Minnesotans for no more than $35 a month over the next five years.
Novo Norodisk caps insulin prices at $35 for Minnesotans
If you rely on insulin, you will be able to buy Novo Nordisk's products for $35 per month due to a settlement announced Monday.
Novo Nordisk’s Ozempic Gets FDA Approval
US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),
FDA approves Novo Nordisk's diabetes drug Ozempic for chronic kidney disease, expanding use in U.S.
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a gradual loss of kidney function.
Novo Nordisk’s Ozempic Gets FDA Approval as Kidney-Disease Treatment
Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, Novo Nordisk said.
2d
Fact Check: Message about insulin price increase announcements originated as satire
A satirical X post saying the three major insulin manufacturers in the United States had announced 2,000%-3,000% price ...
6d
on MSN
Why Novo Nordisk Stock Jumped a Lucky 7.7% Today
On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
All aboard feared dead
Los Angeles wildfire updates
Signs education orders
Agency halts events
Victims of DC plane crash
Ex-FDNY chief pleads guilty
'The Voice' alum dies at 44
Gun trafficking indictments
Lawsuit to keep records
Jury weighs charges
Bird flu 'widespread' in MA
Plans job, output cuts in US
FDA upgrades recall
Presidential historian dies
Zeldin confirmed by Senate
First spacewalk together
US economy grew 2.3%
In talks to invest in OpenAI
Syria’s transitional pres
Witkoff meets Netanyahu
Hamas frees more hostages
Senate confirmation hearing
DOJ weighs dropping case?
Wildfire erupts in NC
Day 2 of Senate hearing
Ebola outbreak in Uganda
Blames DEI for crash
Pushes for earlier trial
Agrees to settle Trump suit
Related topics
Minnesota
United States
Ozempic
Sanofi
Eli Lilly and Company
Feedback